Literature DB >> 6140144

Metabolism of ketotifen by human liver microsomes. In vitro characterization of a tertiary amine glucuronidation.

J F Le Bigot, T Cresteil, J R Kiechel, P Beaune.   

Abstract

Biotransformation of ketotifen was investigated in vitro using human liver microsomes. Three of the four metabolic pathways observed in vivo in man were exhibited under the conditions of incubation, namely demethylation, N-oxidation, and N-glucuronidation, the absent route being the ketoreduction, which probably has a cytosolic localization. The kinetic parameters of the N-glucuronidation (KM for ketotifen and UDPGA and Vmax) were determined with native and detergent-treated microsomes. Treatment by Triton X-100 increased by about 3-fold the conjugation reaction. No sex difference was observed and N-glucuronidation did not seem to be inhibited either by bilirubin or by 4-nitrophenol. Thus, human liver microsomes are a useful and suitable in vitro model for studying metabolic routes, specific for man, as in the case of ketotifen. Obviously, the results obtained can only reflect partially the multiplicity of in vivo events and interpretation has to be complemented by investigations with other models.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140144

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy.

Authors:  Erin Milner; Jason Sousa; Brandon Pybus; Jennifer Auschwitz; Diana Caridha; Sean Gardner; Kristina Grauer; Erin Harris; Mark Hickman; Michael P Kozar; Patricia Lee; Susan Leed; Qigui Li; Victor Melendez; Jay Moon; Franklyn Ngundam; Michael O'Neil; Sandi Parriott; Brittney Potter; Rick Sciotti; Anchalee Tangteung; Geoffrey S Dow
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03       Impact factor: 2.441

Review 2.  Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.

Authors:  S M Grant; K L Goa; A Fitton; E M Sorkin
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.